In the following video, Motley Fool health-care analyst David Williamson discusses a new E.U. approval for Gilead (NASDAQ:GILD) for its quad pill HIV drug cocktail, which has shares up 2% to near all-time highs. David tells investors why this is just one more piece to the puzzle for Gilead, as it continues to build its empire in the treatment of HIV.
- Mar 22, 2013 at 9:02PM
- Health Care